Precision Biosciences Inc (DTIL)

$5.02 +0.01 (0.20%)
Market Cap 52.96M
Revenue (ttm) 68.70M
Net Income (ttm) 7.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 10.44%
Debt to Equity Ratio 0.40
Volume 99,000
Avg Vol 165,188
Day's Range N/A - N/A
Shares Out 10.55M
Stochastic %K 56%
Beta 1.59
Analysts Strong Sell
Price Target $34.50

Latest News on DTIL

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Apr 15, 2025, 7:01 AM EDT - 5 days ago

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 7:01 AM EDT - 19 days ago

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Mar 26, 2025, 7:01 AM EDT - 25 days ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Mar 21, 2025, 7:01 AM EDT - 4 weeks ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Mar 20, 2025, 7:01 AM EDT - 4 weeks ago

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 19, 2025, 7:01 AM EDT - 4 weeks ago

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Mar 17, 2025, 7:01 AM EDT - 4 weeks ago

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Mar 12, 2025, 8:00 AM EDT - 5 weeks ago

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 24, 2025, 7:01 AM EST - 7 weeks ago

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Feb 19, 2025, 2:27 PM EST - 2 months ago

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Feb 19, 2025, 7:01 AM EST - 2 months ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Jan 29, 2025, 7:01 AM EST - 2 months ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Jan 10, 2025, 2:18 PM EST - 3 months ago

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 10:01 AM EST - 3 months ago

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Jan 9, 2025, 8:00 AM EST - 3 months ago

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Dec 18, 2024, 7:01 AM EST - 4 months ago

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming November Investor Conferences

Nov 21, 2024, 7:01 AM EST - 5 months ago

Precision BioSciences to Participate in Upcoming November Investor Conferences

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Nov 15, 2024, 7:00 AM EST - 5 months ago

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 4, 2024, 7:01 AM EST - 5 months ago

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Oct 29, 2024, 7:01 AM EDT - 6 months ago

Precision BioSciences to Report Third Quarter Results on November 4, 2024

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Oct 28, 2024, 7:01 AM EDT - 6 months ago

Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Oct 24, 2024, 4:15 PM EDT - 6 months ago

Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Oct 24, 2024, 8:47 AM EDT - 6 months ago

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Oct 21, 2024, 7:01 AM EDT - 6 months ago

Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Oct 16, 2024, 7:01 AM EDT - 6 months ago

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Oct 3, 2024, 7:01 AM EDT - 7 months ago

Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Sep 30, 2024, 7:01 AM EDT - 7 months ago

Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 7:01 AM EDT - 7 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Sep 12, 2024, 7:15 AM EDT - 7 months ago

Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Sep 4, 2024, 7:01 AM EDT - 8 months ago

Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Sep 3, 2024, 7:01 AM EDT - 8 months ago

Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Aug 9, 2024, 7:01 AM EDT - 9 months ago

Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 1, 2024, 7:15 AM EDT - 9 months ago

Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences to Participate in Upcoming August Investor Conferences

Jul 31, 2024, 7:01 AM EDT - 9 months ago

Precision BioSciences to Participate in Upcoming August Investor Conferences

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Jul 29, 2024, 4:15 PM EDT - 9 months ago

Precision BioSciences to Report Second Quarter Results on August 1, 2024

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Jul 8, 2024, 7:01 AM EDT - 10 months ago

Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Jul 1, 2024, 7:01 AM EDT - 10 months ago

Precision BioSciences Announces its Addition to the Russell Microcap® Index

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Jun 27, 2024, 7:01 AM EDT - 10 months ago

Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.

Jun 20, 2024, 7:00 AM EDT - 10 months ago

Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D.

Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress

Jun 5, 2024, 7:01 AM EDT - 11 months ago

Precision BioSciences Presents New Preclinical Safety Data for PBGENE-HBV Clinical Candidate at the European Association for the Study of the Liver Congress

Precision BioSciences to Participate in Upcoming June Investor Conferences

May 30, 2024, 7:00 AM EDT - 11 months ago

Precision BioSciences to Participate in Upcoming June Investor Conferences

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024, 7:00 AM EDT - 1 year ago

Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

May 8, 2024, 8:15 AM EDT - 1 year ago

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement

Precision BioSciences to Report First Quarter Results on May 13, 2024

May 7, 2024, 4:30 PM EDT - 1 year ago

Precision BioSciences to Report First Quarter Results on May 13, 2024

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

May 7, 2024, 8:30 AM EDT - 1 year ago

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE's Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

May 7, 2024, 8:00 AM EDT - 1 year ago

iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

May 1, 2024, 7:05 AM EDT - 1 year ago

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

Apr 16, 2024, 4:15 PM EDT - 1 year ago

Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics

iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.

Apr 4, 2024, 11:00 AM EDT - 1 year ago

iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update

Mar 27, 2024, 6:45 AM EDT - 1 year ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update